These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 10362259

  • 1. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors.
    Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld B, Polakis P, Matrisian LM.
    Oncogene; 1999 May 06; 18(18):2883-91. PubMed ID: 10362259
    [Abstract] [Full Text] [Related]

  • 2. Tcf binding sequence and position determines beta-catenin and Lef-1 responsiveness of MMP-7 promoters.
    Gustavson MD, Crawford HC, Fingleton B, Matrisian LM.
    Mol Carcinog; 2004 Nov 06; 41(3):125-39. PubMed ID: 15457508
    [Abstract] [Full Text] [Related]

  • 3. The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors.
    Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA, Matrisian LM.
    Mol Cell Biol; 2001 Feb 06; 21(4):1370-83. PubMed ID: 11158322
    [Abstract] [Full Text] [Related]

  • 4. Down-regulation of monocyte chemotactic protein-3 by activated beta-catenin.
    Fujita M, Furukawa Y, Nagasawa Y, Ogawa M, Nakamura Y.
    Cancer Res; 2000 Dec 01; 60(23):6683-7. PubMed ID: 11118053
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc.
    Sasaki T, Suzuki H, Yagi K, Furuhashi M, Yao R, Susa S, Noda T, Arai Y, Miyazono K, Kato M.
    Cancer Res; 2003 Feb 15; 63(4):801-6. PubMed ID: 12591729
    [Abstract] [Full Text] [Related]

  • 7. Beta- and gamma-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer.
    Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, Rimm DL, Costa J, Fearon ER.
    Cell Growth Differ; 1999 Jun 15; 10(6):369-76. PubMed ID: 10392898
    [Abstract] [Full Text] [Related]

  • 8. Differential formation of beta-catenin/lymphoid enhancer factor-1 DNA binding complex induced by nitric oxide in mouse colonic epithelial cells differing in adenomatous polyposis coli (Apc) genotype.
    Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM.
    Cancer Res; 2000 Jul 01; 60(13):3379-83. PubMed ID: 10910042
    [Abstract] [Full Text] [Related]

  • 9. Transactivation of vimentin by beta-catenin in human breast cancer cells.
    Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM.
    Cancer Res; 2003 May 15; 63(10):2658-64. PubMed ID: 12750294
    [Abstract] [Full Text] [Related]

  • 10. Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation.
    Daniels DL, Weis WI.
    Nat Struct Mol Biol; 2005 Apr 15; 12(4):364-71. PubMed ID: 15768032
    [Abstract] [Full Text] [Related]

  • 11. Rare activation of the TCF/beta-catenin pathway in ovarian cancer.
    Furlong MT, Morin PJ.
    Gynecol Oncol; 2000 Apr 15; 77(1):97-104. PubMed ID: 10739697
    [Abstract] [Full Text] [Related]

  • 12. Identification of MYCBP as a beta-catenin/LEF-1 target using DNA microarray analysis.
    Jung HC, Kim K.
    Life Sci; 2005 Jul 29; 77(11):1249-62. PubMed ID: 15979100
    [Abstract] [Full Text] [Related]

  • 13. Dynamic expression of Lef/Tcf family members and beta-catenin during chick gastrulation, neurulation, and early limb development.
    Schmidt M, Patterson M, Farrell E, Münsterberg A.
    Dev Dyn; 2004 Mar 29; 229(3):703-7. PubMed ID: 14991726
    [Abstract] [Full Text] [Related]

  • 14. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways.
    Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC.
    Cancer Res; 2003 Feb 01; 63(3):728-34. PubMed ID: 12566320
    [Abstract] [Full Text] [Related]

  • 15. Selective targeting to the hyperactive beta-catenin/T-cell factor pathway in colon cancer cells.
    Chen RH, McCormick F.
    Cancer Res; 2001 Jun 01; 61(11):4445-9. PubMed ID: 11389074
    [Abstract] [Full Text] [Related]

  • 16. Constitutive activation of Wnt/beta-catenin signaling pathway in migration-active melanoma cells: role of LEF-1 in melanoma with increased metastatic potential.
    Murakami T, Toda S, Fujimoto M, Ohtsuki M, Byers HR, Etoh T, Nakagawa H.
    Biochem Biophys Res Commun; 2001 Oct 19; 288(1):8-15. PubMed ID: 11594745
    [Abstract] [Full Text] [Related]

  • 17. Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation.
    Mariadason JM, Bordonaro M, Aslam F, Shi L, Kuraguchi M, Velcich A, Augenlicht LH.
    Cancer Res; 2001 Apr 15; 61(8):3465-71. PubMed ID: 11309309
    [Abstract] [Full Text] [Related]

  • 18. Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin/T-cell factor complex.
    Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin YM, Nakamura Y.
    Cancer Res; 2003 Oct 01; 63(19):6116-20. PubMed ID: 14559787
    [Abstract] [Full Text] [Related]

  • 19. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells.
    de la Taille A, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, Buttyan R, Chopin D.
    Clin Cancer Res; 2003 May 01; 9(5):1801-7. PubMed ID: 12738737
    [Abstract] [Full Text] [Related]

  • 20. Beta-catenin can act as a nuclear import receptor for its partner transcription factor, lymphocyte enhancer factor-1 (lef-1).
    Asally M, Yoneda Y.
    Exp Cell Res; 2005 Aug 15; 308(2):357-63. PubMed ID: 15936755
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.